HOWL (Werewolf Therapeutics) Cash-to-Debt : 2.99 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Werewolf Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Werewolf Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2024 was 2.99.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Werewolf Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for Werewolf Therapeutics's Cash-to-Debt or its related term are showing as below:

HOWL' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.59 Med: 7.26 Max: 36.43
Current: 2.99

During the past 6 years, Werewolf Therapeutics's highest Cash to Debt Ratio was 36.43. The lowest was 2.59. And the median was 7.26.

HOWL's Cash-to-Debt is ranked worse than
61.53% of 1487 companies
in the Biotechnology industry
Industry Median: 7.42 vs HOWL: 2.99

Werewolf Therapeutics Cash-to-Debt Historical Data

The historical data trend for Werewolf Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Werewolf Therapeutics Cash-to-Debt Chart

Werewolf Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

36.43

10.06

8.81

2.59

2.99

Werewolf Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															2.59	2.72	3.69	3.34	2.99

Competitive Comparison of Werewolf Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Werewolf Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Werewolf Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Werewolf Therapeutics's Cash-to-Debt falls into.

Save

Werewolf Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Werewolf Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	110.995	/	(1.557	+	35.53)
	=	2.99

Werewolf Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	110.995	/	(1.557	+	35.53)
	=	2.99

Werewolf Therapeutics (NAS:HOWL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Werewolf Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Werewolf Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Werewolf Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Werewolf Therapeutics Inc (NAS:HOWL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472

Website

https://www.werewolftx.com

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Executives

Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Luke Evnin	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116
Meeta Chatterjee	director	C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michael A. Sherman	director	3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Chulani Karunatilake	officer: Chief Technology Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Reid Leonard	officer: Chief Operating Officer	1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mpm Oncology Innovations Fund Lp	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142
Longwood Fund Iii Gp, Llc	10 percent owner	800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199
Derek Dirocco	director	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Moshe Arkin	10 percent owner	6 HACHOSHLIM ST., HERZELIA L3 4672406
Alon Lazarus	director, 10 percent owner	C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421
Daniel J Hicklin	director, 10 percent owner, officer: See Remarks
Sphera Funds Management Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Management Lp	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520
Sphera Global Healthcare Gp Ltd.	10 percent owner	4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520